The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Netflix, Inc ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Wall Street Zen downgraded Eli Lilly from a "buy" to a "hold" rating, signaling caution amid a flurry of mixed analyst views. Despite this, Eli Lilly still holds strong support from other firms like ...

Eli Manning shares his impression of Ole Miss quarterback Austin Simmons, who is in Louisiana at the Manning Passing Academy.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

As the weight loss treatment space reaches a new saturation point, Novo Nordisk, Eli Lilly and their closest—but still distant—competitors continue to vie for a greater share of the ever- expanding ...

Kinase Inhibitors in Autoimmune Diseases Market Research 2025-2035, Featuring Pfizer, Eli Lilly and Co, Reistone Biopharma, Incyte, BMS, Galapagos, Aclaris Therapeutics, Kadmon, Sanofi, Ono - ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.